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ARTICLE
Recurrent horizontal transfer identifies
mitochondrial positive selection in a
transmissible cancer
Andrea Strakova et al.#
Autonomous replication and segregation of mitochondrial DNA (mtDNA) creates the
potential for evolutionary conflict driven by emergence of haplotypes under positive selection
for ‘selfish’ traits, such as replicative advantage. However, few cases of this phenomenon
arising within natural populations have been described. Here, we survey the frequency of
mtDNA horizontal transfer within the canine transmissible venereal tumour (CTVT), a
contagious cancer clone that occasionally acquires mtDNA from its hosts. Remarkably, one
canine mtDNA haplotype, A1d1a, has repeatedly and recently colonised CTVT cells, recur-
rently replacing incumbent CTVT haplotypes. An A1d1a control region polymorphism pre-
dicted to influence transcription is fixed in the products of an A1d1a recombination event and
occurs somatically on other CTVT mtDNA backgrounds. We present a model whereby
‘selfish’ positive selection acting on a regulatory variant drives repeated fixation of A1d1a
within CTVT cells.
https://doi.org/10.1038/s41467-020-16765-w OPEN
#A list of authors and their affiliations appears at the end of the paper.
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Mammalian cells carry tens to thousands of copies of themitochondrial genome (mtDNA), an autonomouslyreplicating ~17,000 base-pair (bp) circular chromosome
encoding genes essential for oxidative energy metabolism. Selec-
tion acts on genetic variation arising in mtDNA at two levels.
First, it can act on cellular or organismal phenotypes produced by
altered mitochondrial function (adaptive selection), and, second,
it can drive changes in the frequency of haplotypes with altered
replicative or segregation potential (selfish selection)1. The latter
has been observed in several experimental and natural settings,
and, if stronger than adaptive selection, has the potential to
maintain or fix deleterious mitochondrial alleles1–5. Selfish
selection may be particularly relevant in the context of ther-
apeutic mitochondrial transplantation, and little is understood of
the extent to which naturally occurring mtDNAs in human or
animal populations vary in ‘selfish’ fitness traits1,2,6,7.
One unusual but particularly valuable natural model for
studying mtDNA dynamics is the canine transmissible venereal
tumour (CTVT). CTVT is a contagious cancer in dogs, which
spreads by the transfer of living cancer cells during mating,
causing genital tumours8. The disease is found worldwide, and
first arose from the somatic cells of an individual ‘founder dog’
that lived several thousand years ago9,10. Although the CTVT
nuclear genome is clonal and represents the DNA of the founder
dog, CTVT mtDNAs are polyclonal and were acquired periodi-
cally by horizontal transfer from transient hosts11,12. Capture of
mtDNAs by CTVT cells results in a natural competition assay,
whereby the relative fitness of diverse pairs of canine mtDNA
haplotypes is assessed in vivo. Here, we identify repeated recent
capture of a single canine mtDNA haplotype, A1d1a, by CTVT.
This haplotype likely confers a selfish selective advantage via a
regulatory polymorphism that may influence mtDNA transcrip-
tion and replication.
Results
Recurrent horizontal transfer of the A1d1a haplotype. We
assessed the frequency of mtDNA capture in a cohort of 539
CTVT tumours collected from 43 countries across all inhabited
continents (Supplementary Data 1). By comparing phylogenetic
trees constructed using nuclear and mtDNA sequences (whole
exomes13 and full-length mtDNA genomes, respectively), we
identified nineteen horizontal transfer events (Fig. 1a, Table 1,
Supplementary Fig. 1, Supplementary Fig. 2, Supplementary
Data 2). Remarkably, eleven of these mtDNA captures involved a
single canine haplotype, known as A1d1a (Fig. 1a, Table 1,
Supplementary Fig. 1, Supplementary Fig. 2, Supplementary
Fig. 3, Supplementary Data 2)14. Despite the relatively high pre-
valence of A1d1a in the CTVT host dog germline population, it is
evident that this haplotype is enriched for horizontal transfers to
CTVT relative to other canine haplotypes (p < 0.001, empirical
p value derived from simulations, statistical significance was
unchanged when restricting analysis to tumour–host pairs,
Methods, Fig. 1b, Supplementary Fig. 4, Supplementary Data 1,
Supplementary Data 3).
CTVT clusters derived from A1d1a horizontal transfers were
observed in eight locations around the world, including Belize,
Chile, Colombia, Grenada, India, Nicaragua, Paraguay and The
Gambia (Fig. 1c, Table 1, Supplementary Fig. 4). The structure of
the nuclear tree indicated that A1d1a replaced the two most
common CTVT haplotypes, CTVT_HT1 and CTVT_HT2, on
seven and four occasions, respectively (Fig. 1, Table 1, Supple-
mentary Fig. 1). Ten of the eleven A1d1a horizontal transfers
were fixed (homoplasmic) within CTVT cells; in the remaining
A1d1a horizontal transfer (HT3, Table 1, Supplementary Data 1),
A1d1a recombined with CTVT_HT1, possibly by copy choice
recombination15, and the two tumours in the cohort derived from
this horizontal transfer each carry a heteroplasmic mixture of
mtDNA recombination products12.
The accumulation of mtDNA somatic mutations (mutations
that have arisen after each horizontal transfer event) provides an
estimate of the time since mtDNA horizontal transfer12. Fourteen
of nineteen horizontal transfer events in CTVT, including all
eleven A1d1a captures, carry very few somatic mutations (mean
0.59 somatic mutations per mtDNA genome in A1d1a horizontal
transfers, excluding variants whose germline or somatic status is
unknown, Fig. 1d, Supplementary Data 4, Methods). Assuming a
CTVT mtDNA somatic mutation rate of 0.0201 mutations per
year (0.0127–0.0393, 95% highest posterior density interval12,13,
Methods), this implies that all A1d1a horizontal transfers
occurred recently, probably within the last few decades (Fig. 1d,
Supplementary Data 4).
It is possible that A1d1a may transfer between cells at a higher
frequency than other haplotypes. To examine this possibility, we
measured A1d1a copy number, a trait that may influence
likelihood of mtDNA donation. MtDNA copy number did not
differ between dog or tumour tissues with A1d1a and those with
other haplotypes (Supplementary Fig. 5). Furthermore, dogs with
germline A1d1a did not cluster on a nuclear phylogenetic tree
(Supplementary Fig. 6), suggesting that it is unlikely that nuclear
genetic features of A1d1a host dogs enable these animals to
donate mtDNA to CTVT more efficiently. Although we cannot
exclude the possibility that A1d1a does indeed transfer between
cells at a higher frequency than other haplotypes, it seems more
plausible that the underlying opportunity for horizontal transfer
is constant between haplotypes, relative to population frequency.
Once within the CTVT cell, traits encoded by A1d1a-specific
variants may bestow a selective advantage relative to other
haplotypes.
Genetic features of the A1d1a haplotype. We annotated the
genetic features of A1d1a, relative to other canine haplotypes, in
order to search for variation that may underlie this haplotype’s
selective advantage. A1d1a carries eight single-nucleotide poly-
morphisms (SNPs) and one short insertion that are unique to this
haplotype (or, in some cases, shared with the related A1d1 hap-
lotype) compared with sixteen other major dog haplotype groups
(Fig. 2a, Supplementary Data 5). Six of these variants occur
within protein-coding genes, one of which is predicted to cause a
non-synonymous change (7593T>C in MT-CO2) (Fig. 2a, Sup-
plementary Data 5). The remaining variants fall within ribosomal
DNA (one variant) and within the mitochondrial control region
(two variants) (Fig. 2a, Supplementary Data 5). The control
region is a non-coding regulatory zone that contains elements
required for the initiation of mtDNA replication and
transcription16,17. Transfer event HT3, in which A1d1a and
CTVT_HT1 have undergone recombination, provides an
opportunity to further refine the candidate region for positive
selection within A1d1a. Using long sequence reads, we phased
recombinant mtDNA haplotypes within the two tumours derived
from HT3 (Methods12). Both HT3 tumours carry a heteroplasmic
pool of recombinant haplotypes; however, an insertion of two
cytosines in the control region, 16660insCC, was the only A1d1a-
specific variant carried by all haplotypes within these tumours
(Fig. 2b). In addition, 16660insCC was twice observed arising as a
somatic mutation, on CTVT_HT1 and CTVT_HT2 mtDNA
backgrounds, respectively (Fig. 2a, Supplementary Data 5).
Together, these findings present 16660insCC as a candidate for
driving A1d1a-positive selection.
16660insCC occurs between conserved sequence block 3
(CSB3) and tRNA-Phe within the canine control region (Fig. 2c).
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Fig. 1 Recurrent and recent horizontal transfer of canine mitochondrial haplotype A1d1a. a MtDNA (left) and nuclear DNA (right) maximum likelihood
phylogenetic trees for 539 CTVT tumours (coloured) and 494 dogs (black). Correspondence between equivalent CTVTs on mtDNA and nuclear trees is
indicated and coloured by mtDNA donor haplotype. Trees are presented as cladograms without informative branch lengths. High resolution trees are
presented in Supplementary Figs. 1 and 2. b Frequencies of 18 canine mtDNA haplotypes within a representative global CTVT host dog population (n=
495) (left), and the number of CTVT horizontal transfer (HT) events involving each haplotype in a population of 539 CTVTs (right). Donor haplotype
(coloured dots) and heteroplasmic horizontal transfer events (asterisks (*) and lighter shading) are shown. Heteroplasmic tumours carry both the parental
and introduced haplotype. The A1d1a heteroplasmic horizontal transfer event involves mtDNA recombination. Bars representing A1d1a are highlighted in
green. c Inferred geographical locations of 19 CTVT mtDNA horizontal transfer events. Each horizontal transfer is represented by a dot coloured by donor
haplotype. If all CTVTs arising from a horizontal transfer were sampled at the same location, then this was inferred as the location of the horizontal
transfer. If CTVTs derived from the horizontal transfer were found in several locations, then the likely site of the horizontal transfer was inferred based on
phylogenetic information12,13. Heteroplasmic horizontal transfer events are indicated with an asterisk (*). d Number of somatic mtDNA mutations acquired
since each horizontal transfer (HT) event. Number of CTVTs (n= 539) belonging to each HT event is indicated. Bars are split into two categories:
darker colour shades represent confident somatic mutations that are polymorphic within each HT group, with error bars representing the mutation range;
lighter colour shades represent variants that are fixed within each HT group, whose somatic or germline status cannot be determined (see Methods). Bars
representing A1d1a HTs are highlighted in green. Donor haplotype (coloured dots) and heteroplasmy (asterisk, *) are shown.
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Table 1 Summary of 19 horizontal transfer (HT) events detected in a population of 539 CTVT tumours.
Horizontal
transfer
Donor haplotype group CTVT haplotype group
replaced
Number of
tumours
Percentage heteroplasmy (%) Locations observed
HT1 A1e Unknown 205 100 Widespread
HT2 A1a1 A1e (HT1) 285 100 Widespread
HT3 A1d1a A1e (HT1) 2 Recombinant Nicaragua
HT4 A1a1 Unknown 6 100 India
HT5 A1d1 A1a1 (HT2) 2 100 Nigeria
HT6 A1a1 A1e (HT1) 2 100 Armenia
HT7 A1a1 A1e (HT1) 1 100 Mexico
HT8 A1d1a A1e (HT1) 7 100 Belize
HT9 A1d1a A1e (HT1) 14 100 Nicaragua
HT10 A1d1a A1e (HT1) 1 100 Nicaragua
HT11 A1d1a A1e (HT1) 1 100 Colombia
HT12 A1d1a A1e (HT1) 1 100 Colombia
HT13 A1d1a A1e (HT1) 1 100 Chile
HT14 A1d1a A1a1 (HT2) 1 100 The Gambia
HT15 A1d1a A1a1 (HT2) 1 100 Grenada
HT16 A1d1a A1a1 (HT2) 3 100 India
HT17 A1d1a A1a1 (HT2) 4 100 Paraguay
HT18 B1 A1e (HT1) 1 ~55 Nicaragua
HT19 A1a1 A1e (HT1) 1 ~15 Nicaragua
Donor haplotype group, incumbent CTVT haplotype that was replaced, number of tumours observed within each horizontal transfer group, percentage heteroplasmy (the fraction of mtDNAs in the
tumour derived from the incoming haplotype) and geographical locations in which tumours were observed are listed for each HT event. The two tumours derived from HT3 each carried a heteroplasmic
mixture of recombinant haplotypes from the incumbent and incoming mtDNAs.
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Fig. 2 Genetic features of the A1d1a haplotype. a Genetic variants unique to the A1d1a haplotype (and in some cases shared with the related A1d1
haplotype, Supplementary Data 5) relative to 16 other dog haplotype groups. Number of somatic occurrences on other non-A1d1a CTVT mtDNA
backgrounds is indicated above each variant. Variants within protein-coding genes are annotated as synonymous (S) or non-synonymous (NS), and other
variants are annotated as occurring within ribosomal RNA (rRNA) or the control region (CR). MtDNA (MT) genome coordinates are indicated. b MtDNA
haplotypes detected using long-read sequencing in the two tumours (labelled tumour 1 and tumour 2) belonging to the HT3 group, in which A1d1a and
CTVT_HT1 have undergone recombination, with a heteroplasmic mixture of recombination products present in each tumour. The region fixed in all
haplotypes in both tumours is indicated with a dotted box. The estimated frequency of each recombinant haplotype (H) within the two tumours’ CTVT cell
mtDNA population is shown. c 16660insCC sequence context and position relative to control region features. Conserved sequence blocks (CSB) 1–3 are
marked, together with the light strand promoter (LSP), heavy strand promoter (HSP) and a ten-nucleotide (nt) repeat block. 16660insCC co-occurs in
A1d1a with 16672C>T, a polymorphism present on several canine haplotypes.
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Although this locus is poorly conserved across species, the
equivalent sequence region within human mtDNA contains one
of the two mitochondrial transcription promoters, the light strand
promoter (LSP). Transcription initiation from LSP produces both
the light strand polycistron and the primer for leading strand
mtDNA replication initiation18,19. Using 5′ rapid amplification of
cDNA ends, we mapped the canine LSP transcriptional start site
(LSP-TSS) to position 16648, 12–15 bp downstream from
16660insCC (Methods). In humans, the transcription initiation
complex recognises a region at an equivalent distance upstream of
the LSP-TSS, suggesting that 16660insCC may lie within the
transcription initiation complex binding module of canine LSP20.
This finding implies that 16660insCC may influence transcrip-
tional activity.
Mitochondrial gene transcript abundance in A1d1a CTVT. In
order to further characterise the effects of 16660insCC on
mtDNA transcription, we performed RNA sequencing on CTVT
tumours carrying the two most abundant CTVT haplotypes
CTVT_HT1 and CTVT_HT2, as well as those with A1d1a. The
A1d1a CTVTs were phylogenetically unrelated on the nuclear
tree, and were derived from three different horizontal transfer
events (Supplementary Fig. 1, Supplementary Data 1, Supple-
mentary Data 6A). Abundance of mtDNA protein-coding gene
RNA, including heavy and light strand transcripts, was reduced in
A1d1a CTVTs compared with CTVT_HT1 and CTVT_HT2
CTVTs (39% decrease in mean transcript abundance; p= 0.015,
two-sided Mann–Whitney test), although there was large varia-
tion in transcript abundance within groups (Fig. 3a, Supple-
mentary Data 6B). Mean mtDNA transcript abundance was also
decreased in a group of tumours carrying 16660insCC (two
tumours) and 16660insC (one tumour) somatic mutations on
CTVT_HT1 and CTVT_HT2 haplotype backgrounds, and car-
rying 16660insCC on a recombinant CTVT_HT1/A1d1a back-
ground (one tumour), although this difference was not
statistically significant (30% decrease in mean transcript abun-
dance; p= 0.093, two-sided Mann–Whitney test) (Fig. 3a, Sup-
plementary Data 6B). Furthermore, 7 of 13 mtDNA genes showed
significantly lower abundance in A1d1a CTVTs compared with
CTVT_HT1 and CTVT_HT2 CTVTs (q < 0.05, two-sided Wald
test with multiple-testing correction; Methods) (Supplementary
Data 6B). Abundance of a set of nuclear-encoded mitochondrially
relevant gene transcripts was unchanged between CTVTs with
A1d1a and those with CTVT_HT1 and HT2 haplotypes (Sup-
plementary Data 6C). Introducing a CC insertion into an
equivalent position to canine 16660 within the human LSP
abolished light strand transcription in an in vitro assay (Supple-
mentary Fig. 7), indicating that the locus is highly relevant for
light strand transcriptional initiation. These analyses implicate
16660insCC as a regulatory variant acting to reduce mtDNA gene
transcription.
Negative selection operating on mtDNA-encoded protein-
coding genes indicates that mitochondrial function is important
MT:16660 INSERTION
2 431
CTVT cell
Host cells
A1d1a
mitochondria
b
CTVT_HT1
CTVT_HT2
CTVT_A1d1a
a mtDNA protein-coding gene transcript mean abundance
0 5000 10,000 15,000
*
CTVT_HT1/HT2+
insCC/insC/Rec
Fig. 3 MtDNA gene transcript abundance and model. a Mean abundance of mtDNA protein-coding gene RNA in CTVT_HT1, CTVT_HT2, CTVT_A1d1a
and CTVT_HT1/HT2+insCC/insC/Rec CTVTs (n= 33). In the group of CTVT_HT1/HT2+insCC/insC/Rec CTVTs (represented in grey), two carry
16660insCC and one carries 16660insC as a somatic mutation on CTVT_HT1 or CTVT_HT2 haplotype backgrounds, and one carries 16660insCC on a
CTVT_HT1/A1d1a recombinant background. Dots represent mean abundances of mtDNA protein-coding gene transcripts in each of the CTVTs from each
group, diamonds indicate mean mtDNA protein-coding gene abundances for each group and bars indicate 95% confidence intervals of the mean. Asterisk
(*), p= 0.015 (two-sided Mann–Whitney test; Methods). Supplementary Data 6B provides batch-corrected transcript abundance data. b A model
explaining repeated CTVT capture of the A1d1a haplotype. (1) All canine mtDNA haplotypes have equal opportunity for CTVT horizontal transfer, relative
to population haplotype frequency. (2) A1d1a mtDNA haplotype carries an insertion in the control region, 16660insCC, which is not present in other
haplotypes, and which may have regulatory functions. (3) MtDNA protein-coding transcript abundance is decreased in tumours with the A1d1a mtDNA
haplotype relative to the two most common CTVT mtDNA haplotypes. (4) After A1d1a mtDNA horizontal transfer, A1d1a becomes homoplasmic through a
selfish replicative advantage.
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for CTVT biology12. Thus, a decline in mtDNA gene transcript
abundance, as observed in A1d1a CTVT, is unlikely to be
adaptive for CTVT cells, although it may be neutral21. Never-
theless, we quantified two possible adaptive phenotypes, mitotic
rate and timing of tumour response to chemotherapy. These traits
did not differ between A1d1a CTVTs and CTVT_HT1 and
CTVT_HT2 CTVTs (Supplementary Fig. 8). Furthermore, the set
of A1d1a-specific polymorphisms does not immediately suggest a
mechanism for adaptive functional relevance (Supplementary
Data 5). Overall, we cannot exclude the possibility that A1d1a is
adaptive for CTVT cells; however, there is no evidence supporting
this hypothesis. Rather, our work supports a model whereby a
regulatory variant in the A1d1a control region reduces transcrip-
tion from this haplotype. Given that transcription and replication
are coupled in mtDNA22,23, we suggest that A1d1a favours
replication over transcription, conferring A1d1a with a replicative
advantage that drives this haplotype to fixation via selfish
selection (Fig. 3b).
Discussion
A survey of CTVT mtDNA diversity revealed that a single canine
mtDNA haplotype, A1d1a, has repeatedly and recently colonised
CTVT cells via horizontal transfer. Although we cannot rule out
the possibilities that A1d1a has an increased propensity for
horizontal transfer, or that it offers an adaptive advantage to
CTVT cells, our data most strongly support a model whereby
A1d1a replaces other mtDNA haplotypes via selfish selection.
MtDNA integrity is important for CTVT biology12, and it has
been proposed that mtDNA exchange per se is under positive
selection via replacement of haplotypes degraded by somatic
mutation11,12. However, assuming that A1d1a is horizontally
transferred at a similar rate to other haplotypes, relative to
population frequency, our observations suggest that most hor-
izontal transfers result in maintenance of incumbent CTVT
mtDNAs, despite their high somatic mutation burden. Perhaps
centuries of haplotype replacement and intracellular haplotype
competition have optimised ‘selfish’ traits within CTVT mtDNAs,
such that few dog haplotypes may now compete with incumbent
CTVT mtDNAs, despite a potential adaptive selective advantage.
On the other hand, given its reduced mtDNA transcript abun-
dance, it is plausible that A1d1a is in fact maladaptive for
CTVT cells, highlighting a possible unexpected deleterious con-
sequence of long-term clonal evolution.
Without knowledge of the underlying frequency of mtDNA
horizontal transfer into CTVT, or of the number of mtDNA
copies transferred per event, the strength of selection operating
on A1d1a cannot be quantified. Furthermore, the lack of
laboratory tools for studying canine mitochondrial replacement,
in particular the unavailability of CTVT cell lines, precludes
direct experimental investigation of this process. However, the
observation of homoplasmic somatic 16660insCC mutations
occurring on non-A1d1a CTVT mtDNAs raises the possibility
that selection operating on this variant may, in some cases, be
sufficient to drive fixation from a single molecule (although we
cannot exclude the possibility that the observed somatic
16660insCC mutations achieved homoplasmy via neutral genetic
drift).
Interestingly, most (14 of 19) horizontal transfer events
observed in this CTVT cohort, including all eleven A1d1a hor-
izontal transfers, occurred recently. This may reflect an expo-
nentially expanding CTVT population13, or, perhaps, a failure of
ancient A1d1a CTVT lineages to persist. However, the frequency
of mtDNA horizontal transfer has been linked to cell stress in a
variety of model systems24,25, and chemotherapy exposure has
been proposed to increase the rate of mtDNA capture26. Thus, it
is possible that the use of chemotherapy, a widespread treatment
for CTVT since the 1980s27,28, has elevated the frequency of
mtDNA capture in CTVT. Veterinarians in all locations where we
observed recent mtDNA horizontal transfers reported che-
motherapy use for CTVT. Furthermore, in some cases, veter-
inarians indicated that animals undergoing chemotherapy were
not routinely isolated from other dogs, creating conditions that
would permit transmission of chemotherapy-exposed CTVT cells.
Varying access to and attitudes towards chemotherapy treatment
in different cultural settings may also explain the apparent over-
representation of horizontal transfer events in Central America
(Fig. 1c), although we cannot exclude the possibility that this
arose by chance. Thus, it is plausible that human intervention
may have influenced the recent emergence of A1d1a CTVT
clusters.
The replicative autonomy of mtDNA provides scope for selfish
haplotype evolution, despite potential deleterious consequences
for cellular or organismal fitness3,4,29. Such evolutionary conflicts
are likely controlled in the germline via safeguarding strategies
imposed during mtDNA bottlenecks in the egg1,30,31. Never-
theless, it has been suggested that these processes may drive
somatic and germline persistence of ‘selfish’ mitochondrial alleles,
some of which may be maladaptive or even pathogenic2,30.
Importantly, the replicative drive of donor and recipient mtDNA
haplotypes should be considered in mitochondrial transplantation
therapy, and may be crucial for success of this procedure1,6,7,32.
Although CTVT is considered a biological oddity, its periodic
uptake and juxtaposition of mitochondrial haplotypes provides
broad and unexpected insights into the evolutionary consequences
of natural polymorphism in mammalian mitochondrial genomes.
Methods
Sample collection and nucleic acid extraction. This study was approved by the
Department of Veterinary Medicine, University of Cambridge, Ethics and Welfare
Committee (reference number CR174). Informed consent for sample collection was
received from the owner, or from another responsible person in the case of
unowned dogs. Tumour and host (gonad, skin, blood or liver) tissue samples were
collected into RNAlater (Invitrogen, Carlsbad, CA, USA) and stored at −20 °C
until processing. Genomic DNA was extracted using the Qiagen DNeasy Blood and
Tissue extraction kit (Qiagen, Hilden, Germany). Total RNA was extracted using
the Qiagen AllPrep extraction kit (Qiagen, Hilden, Germany). Sample information
is presented in Supplementary Data 1.
Confirmation of CTVT diagnosis. Quantitative PCR assays were performed to
confirm CTVT diagnosis by detection of the CTVT-specific LINE-MYC genomic
rearrangement12, or by histopathology analysis.
Exome library preparation and sequencing. Illumina whole genome DNA
sequencing libraries with insert size 100–400 base pairs (bp) were constructed using
standard methods according to the manufacturer’s instructions. Probes targeting
the canine protein-coding genome and microRNAs were designed (43Mb, Agilent
Technologies, Santa Clara, CA, USA; ELID IDs 0679931, 0679881, 0679921,
0679911, 0679901 and 0679891), and used to capture the canine exome using
standard methods according to the manufacturer’s instructions. Sequencing was
performed with 75-bp paired-end reads on an Illumina HiSeq2000 instrument,
using V3 and V4 sequencing chemistry (Illumina, San Diego, CA, USA). Tumours
and hosts were sequenced to an average exome depth of ~132× and ~104×,
respectively. Sequence reads were aligned to the CanFam3.1 canine reference
genome33,34 using the Burrows–Wheeler Aligner’s Backtrack Alignment35 (BWA-
backtrack) v0.5.9-r16+rugo with options ‘-l 32 -t 6’. Information on the genomic
composition of the sequenced exome regions is detailed in Baez-Ortega et al.13.
RNA sequencing. Stranded RNA sequencing libraries with insert size 100–300 bp
were generated for 33 CTVTs (1208Ta-Dog, 1210Ta-Dog, 1247Ta-Dog, 126Ta-
Dog, 131Ta-Dog, 1532Ta-Dog, 24Ta-Dog, 335Ta-Dog, 341Ta-Dog, 355Ta-Dog,
365Tb-Dog, 366Ta-Dog, 410Ta-Dog, 423Ta-Dog, 439Tb-Dog, 459Ta-Dog, 464Ta-
Dog, 468Ta-Dog, 550Ta-Dog, 556Tb-Dog, 559Ta-Dog, 560Ta-Dog, 608Ta-Dog,
609Ta-Dog, 645Ta-Dog, 652Ta-Dog, 666Ta-Dog, 683Ta-Dog, 773T1a-Dog, 79Ta-
Dog, 809Ta-Dog, 851Ta-Dog and 855Ta-Dog) with the Ribo-Zero ribosomal RNA
removal kit (Illumina, San Diego, CA, USA) using standard methods according to
the manufacturer’s instructions. The libraries were sequenced with 75-bp paired-
end reads on an Illumina HiSeq4000 instrument (Illumina, San Diego, CA, USA) to
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an average depth of ~168×13. Samples were processed in three batches (Supple-
mentary Data 6A).
Substitution calling and post processing. Substitutions in nuclear genomes were
called using Platypus36 v0.8.1 as part of a bespoke computational pipeline
(Somatypus v1.3, https://github.com/baezortega/somatypus)13. Substitutions in
mitochondrial genomes were called using the same bespoke computational pipeline
as above, with the following modifications in the individual filtering and merging
step, and in the final filtering step: substitution called if ≥3 supporting reads with
mapping quality ≥ 20 and base quality ≥ 20 were detected, and base qualities within
10 bp of the ends of reads were set to 0.
Indel calling. Small insertions and deletions (indels) in mitochondrial genomes
were extracted from whole exome sequencing data using samtools and
bcftools37,38. Samtools v0.1.18 mpileup with options ‘-C50’ and ‘-gf’ was used to
create raw bcf files from indexed bam files, and indels were called with bcftools
v0.1.17 view, options ‘-bvcg’.
Phylogenetic analyses. For maximum likelihood topology inference, the mito-
chondrial DNA (mtDNA) phylogenetic tree represented in Fig. 1a and Supple-
mentary Fig. 2 was constructed with 539 CTVTs, 494 dogs (Supplementary Data 1
and 2), the CanFam3.1 canine mitochondrial reference sequence, and rooted with
two coyote genomes (GenBank accession numbers: DQ480510.1, DQ480509.1).
We phased and extracted distinct haplotypes in heteroplasmic tumours using
variant allele fractions or, in tumours belonging to HT3, using PacBio sequencing
(see section ‘MtDNA recombination analysis’), and each haplotype was included in
the tree as a separate sample (Supplementary Data 2). One dog sample (15 Ha,
Supplementary Data 1) was discarded due to CTVT contamination. The tree
inference was performed with RAxML39 v8.2.9 using a maximum likelihood
method with a generalised time-reversible (GTR) substitution model. In total, 500
bootstrap replicates were produced using the rapid bootstrapping algorithm
implemented in RAxML v8.2.9.
The nuclear DNA maximum likelihood phylogenetic tree represented in Fig. 1a
and Supplementary Fig. 1 was constructed using 148,030 nuclear CTVT somatic
mutations genotyped across the same set of 539 CTVT tumours and 494 normal
dogs (Supplementary Data 1), using a GTR substitution model with a Gamma
model of site heterogeneity in RAxML13,39. In total, 500 bootstrap replicates were
produced using the rapid bootstrapping algorithm implemented in RAxML v8.2.9.
For tanglegram construction, correspondence between equivalent CTVT
tumours on mtDNA and nuclear trees was assessed using a tanglegram constructed
in Dendrocope40 v3.5.10.
For horizontal transfer group inference, mtDNA horizontal transfer was
inferred if discordance was observed between mtDNA and nuclear phylogenetic
trees. Heteroplasmic horizontal transfer was inferred in tumours carrying two or
more distinct mtDNA haplotypes, all present at more than 10% frequency, and not
explained by the matched host haplotype (Table 1, Supplementary Data 2).
Heteroplasmic tumours carried haplotypes from the parental CTVT and the newly
transferred haplotype, except for the HT3 group, which carried a heteroplasmic
mixture of recombinant haplotypes. Groups of CTVTs were inferred to belong to a
single horizontal transfer event if they clustered together on both the mtDNA and
nuclear phylogenetic trees (Fig. 1a, Supplementary Figs. 1 and 2).
Dog haplotype assignment. The haplotype naming system was adapted from the
cladistic canine mtDNA phylogeny nomenclature proposed by Fregel et al.14. An
mtDNA phylogenetic tree was constructed with 495 dogs (Supplementary Data 1),
the CanFam3.1 canine mitochondrial reference sequence, and rooted with two
coyotes (GenBank accession numbers: DQ480510.1, DQ480509.1) (Supplementary
Fig. 3). The tree inference was performed with RAxML39 v8.2.9 using a max-
imum likelihood method with a GTR substitution model. The tree topology was
used to assign dogs into one of the following 18 haplotypes: A1, A1a1, A1b, A1c,
A1d1, A1d1a, A1d2, A1e, A1f, A1h, A2, A4, A5, A6, B1, B2, C1 and C2 (Fig. 1b,
Supplementary Fig. 3, Supplementary Data 3).
Timing analysis of horizontal transfer events. CTVT_HT1 and CTVT_HT2
diverged ~469.28 years ago (240.34–744.31, 95% highest posterior density interval)13.
Given that the mean number of CTVT_HT2 somatic mtDNA mutations = 9.437,
and assuming a constant mtDNA mutation rate, we estimate a CTVT mtDNA
mutation rate of 0.0201 mutations per year (0.0127–0.0393, 95% highest poster-
ior density interval) (Supplementary Data 4). The number of substitutions in hor-
izontal transfer events HT1, HT2, HT4 and HT5 is presented as in Strakova et al.12.
In HT3, somatic or germline status of substitutions could not be determined due to
mtDNA recombination.
A1d1a horizontal transfer frequency modelling. Simulations were performed to
calculate the probability of A1d1a horizontal transfer occurring at the frequency
observed, given the observed frequency of haplotypes in the dog population
(Supplementary Data 3), and the assumption that each haplotype has an equal
horizontal transfer opportunity. The simulation was performed in R41 over 10000
repetitions, with randomisation seed set to 76. The empirical p value was derived
from the proportion of simulations with the number of A1d1a horizontal transfers
equal to or exceeding the observed value. A more conservative analysis was per-
formed that included only matched tumour–host pairs. The code used for this
analysis is available at https://github.com/TransmissibleCancerGroup/Mixed.
A1d1a mtDNA copy number. MtDNA copy number was calculated for normal
canine ovarian (n= 42) and testicular (n= 41) tissue, as well as for CTVT tumours
(n= 337) (Supplementary Fig. 5). The following equation was used to calculate the
mtDNA copy number: (mtCOV-T/nuclCOV-T) × P, where mtCOV-T= average
coverage across the mitochondria × mtDNA tumour fraction, nuclCOV-T=
average coverage across the nuclear genome × nuclear tumour fraction, and P=
ploidy. Ploidy was estimated as two for both CTVT tumours and dogs42. MtDNA
tumour fraction was estimated from variant allele fraction (VAF, i.e. number of
reads supporting the substitution variant as a fraction of the total number of
reads covering the substitution variant position). Nuclear tumour fraction was
estimated from whole exome sequencing data using the following equation: (mode
of T-VAF) × 2, where T-VAF= somatic tumour variant allele fraction13. Statistical
significance was tested using an unpaired two-tailed Student’s t test implemented
in R41.
Nuclear relationships of A1d1a dogs. A neighbour-joining cladogram was con-
structed using 136,880 canine germline variants genotyped across 495 CTVT host
dogs (Supplementary Data 1) and 7 wolves obtained from the Dog Genome SNP
Database (ftp://download.big.ac.cn/dogsd/bam/)43 (Sample IDs: ISW, CRW, CHW,
LUPWRUS00001, LUPWRUS00002, LUPWRUS00003 and LUPWCHN00001)
(Supplementary Fig. 6)13. To account for the presence of heterozygous and
homozygous variants, distances between the aligned sequences were calculated
using the p-distance metric, as implemented in the ‘dist.p’ function of the phan-
gorn44 v2.3.1 package for R. The phylogenetic tree was constructed using the
neighbour-joining algorithm, as implemented in the ‘NJ’ function of the phangorn
package.
A1d1a-specific substitutions and indels. Substitutions and small insertions and
deletions (indels), which were common and unique to A1d1a and, in some cases,
the related A1d1 haplotype, were identified through filtering against other CTVT
and dog samples (CTVTs belonging to HT3, which has undergone recombination
between CTVT_HT1 and A1d1a, were not considered in defining A1d1a-specific
variants) (Supplementary Data 1 and 5). Indels were validated visually using
Integrative Genomics Viewer (IGV)45,46. Annotation was performed using Variant
Effect Predictor47 (Supplementary Data 5), and the functional relevance of each
variant was assessed, where possible, by aligning the region to humans and
assessing variants using Mitomap48. Somatic occurrence of each A1d1a-specific
genetic variant was assessed in the set of 495 CTVT tumours (Supplementary
Data 1 and 5).
MtDNA recombination analysis. Potential recombinant samples were identified
by searching for outliers on the mtDNA phylogenetic tree, and by visualising
mtDNA VAF plotted against mtDNA genome coordinate. Standard PacBio
genomic libraries were created using 5 µg of genomic DNA from samples 559T and
1315T, belonging to HT3, not utilising shearing or amplification techniques12.
PacBio (Pacific Biosciences, Menlo Park, CA, USA) data reads aligned to Can-
Fam3.1 mtDNA genome were viewed in SMRT view v2.3.0 (Pacific Biosciences,
Menlo Park, CA, USA) and in IGV45,46. The three or two most common haplo-
types in 559T and 1315T, respectively, were phased by visual inspection, as shown
in Fig. 2b. Additional haplotypes present at a low level (less than 5%) were also
identified in both samples, and are not shown in Fig. 2b.
Gene expression analysis. Two FASTQ files containing raw forward and reverse
reads, respectively, were generated from each tumour BAM file using the bio-
bambam249 v2.0.79 software, and gene expression was estimated via transcript
abundance quantification using the Salmon50 v0.8.2 software13. Gene-specific
differential expression analysis was performed using the DESeq251 v1.14.1 R
package to compare CTVT_A1d1a expression against CTVT_HT1 and
CTVT_HT2 expression (Supplementary Data 6). To account for batch effects, both
the batch and HT group of each sample were included as variables in the design
formula for the differential expression analysis. Because the analysis was directed to
mtDNA-encoded genes (n= 13, Supplementary Data 6B) and nuclear-encoded
mitochondrially relevant genes (n= 7, Supplementary Data 6C), restricted
hypothesis testing was performed, such that only these genes were considered when
adjusting p values via Benjamini–Hochberg multiple-testing correction.
For assessment of overall changes in transcript abundance between HT groups,
raw read counts of mtDNA protein-coding genes were transformed using the rlog
function in DESeq2 and subjected to batch effect correction using the limma52
v3.38.3 R package. After batch effect correction, the log transformation was
reversed, and the corrected estimates were scaled to render them comparable to the
original transcript abundance estimates. Mean abundances of mtDNA protein-
coding genes per sample and per HT group were calculated from the batch-
corrected estimates (Fig. 3a, Supplementary Data 6B). Statistical significance of
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overall transcript abundance differences between groups was tested using a two-
sided Mann–Whitney test (as implemented in R41) on the batch-corrected mtDNA
transcript abundances per gene in each group (not the mean abundances). To
confirm the result from batch-corrected estimates, uncorrected mtDNA transcript
abundance estimates for group CTVT_A1d1a and groups CTVT_HT1 and
CTVT_HT2 were compared independently for batches 1 and 2, and transcript
abundance was found to be comparably decreased in group CTVT_A1d1a for each
batch (49% decrease and p= 0.0002 for batch 1; 46% decrease and p= 0.088 for
batch 2; batch 2 had only one A1d1a CTVT).
Canine LSP mapping. The MDCK cell line (ECACC 84121903) was grown
adherently in DMEM (31966047, Gibco) with penicillin–streptomycin (10,000 U/
ml, Gibco) and 10% foetal bovine serum (10270106, Gibco). Mitoplast extract was
isolated53, and RNA was extracted using the miRNeasy Mini Kit (Qiagen, Hilden,
Germany). The position of the LSP transcriptional start site (LSP–TSS) was
mapped using 5′/3′ RACE kit, 2nd Generation (Roche, Basel, Switzerland),
according to the manufacturer’s instructions. Briefly, cDNA was synthesised using
a pre-designed LSP-P1 primer (5′-GTA AAC TCA TGT CAT CTA TTA TAC-3′),
purified and tailed using dATP and terminal transferase. A polymerase chain
reaction (PCR) was performed using a specific LSP-P2 primer (5′-CTT ATT TAT
GTC CCG CCA AAC C-3′) and an oligo dT-Anchor primer. The PCR product was
gel-purified and sequenced to identify the LSP-TSS.
To identify the mtDNA haplotype of MDCK, DNA was extracted using the
AllPrep extraction kit (Qiagen, Hilden, Germany), and the region between
mitochondrial positions 16499-111 was amplified in a PCR reaction using the
primers F-16499 (5′-CCC CGT AAA CTC ATG TCA TCT ATT-3′) and R-111 (5′-
GTG GAG GCT TGC ATG TGT AA-3′). The PCR product was purified using the
QIAquick kit (Qiagen, Hilden, Germany) and sequenced to confirm the presence of
16660insCC, indicating that MDCK has haplotype A1d1a. We confirmed that the
LSP–TSS was unchanged in non-A1d1a canine cells by performing promoter
mapping in a second canine cell line (canine fibroblast cell line grown using sample
135H) with haplotype B1.
MtDNA transcription assays. Recombinant human POLRMT, TFAM, TFB2M
and TEFM were expressed and purified54,55. Templates for transcription reactions
consisted of pUC18 containing human mtDNA sequence (positions 1–477 for LSP-
containing templates and positions 1–742 for templates containing both LSP and
HSP, heavy strand promoter), cloned between BamHI and HindIII restriction sites.
Constructs were created to include a wild-type template, +CC template to model
canine 16660insCC at the equivalent position in the human mitochondrial genome
(i.e. ~15 bp upstream of LSP transcription start site) and +TT template to model
16660insCC, and to reflect the stretch of thymines in the human sequence.
Templates were linearised with either BamHI or HindIII (as indicated, Supple-
mentary Fig. 7) to generate the appropriate runoff transcription products. Tran-
scription reactions (25 μl) contained 500 fmol POLRMT, 500 TFB2M, TFAM
(as indicated, Supplementary Fig. 7), 90 fmol template DNA, 10 mM Tris-HCl
(pH 8.0), 10 mM MgCl2, 64 mM NaCl, 100 μg/ml BSA, 1 mM DTT, 100 μM ATP,
100 μM CTP, 100 μM GTP, 10 μM UTP, 0.02 μM [α-32P] UTP (3000 Ci/mmol)
and 4 units of murine RNase inhibitor (New England Biolabs, Ipswich, MA, USA).
Where indicated (Supplementary Fig. 7), reactions also contained 1 pmol TEFM.
Reactions were incubated at 32 °C for 30min, then stopped by the addition of 200 μl
of stop buffer (10mM Tris-HCl (pH 8.0), 0.2M NaCl, 1 mM EDTA, 150 μg/ml
proteinase K and 0.1mg/ml glycogen) and incubated at 42 °C for 45min. Reactions
were then ethanol-precipitated and resuspended in 10 μl of loading buffer (98%
formamide, 10mM EDTA, 0.025% xylene cyanol FF and 0.025% bromophenol blue).
Samples were separated by 4% denaturing PAGE (1× TBE, 7M urea) and imaged
using autoradiography.
Canine mtDNA transcription reactions were also attempted. MDCK mitoplast
lysate was isolated53. Templates for transcription reactions consisted of pEX-A128
containing canine mtDNA sequence (positions 16430–16727 for templates
assumed to contain both LSP and HSP). Constructs were created to include a non-
A1d1a template and an A1d1a template containing 16660insCC. Templates were
linearised with BamHI and NotI, or EcoRI and SspI to generate runoff
transcription products of variable lengths. Transcription reactions (25 µl) were
performed and analysed as described above, with varying amounts of freshly
extracted MDCK mitoplast lysate (1.25, 2.5 µl) and varying amounts of template
DNA (100 and 200 fmol). No transcription from canine LSP or HSP was detected
using this method.
Mitotic rate. A blinded histopathology scoring study was performed by a single
scorer, under the guidance of a veterinary pathologist. Twenty-eight A1d1a CTVT
histology samples were scored, together with 31 CTVT_HT1 and CTVT_HT2
CTVT controls. CTVT_HT1 and CTVT_HT2 controls were phylogenetically
matched with A1d1a tumours. The 28 A1d1a CTVTs belonged to 8 horizontal
transfer groups (HT3, 2 tumours; HT8, 6 tumours; HT9, 13 tumours; HT10, 1
tumour; HT13, 1 tumour; HT14, 1 tumour; HT16, 1 tumour; HT17, 3 tumours).
Histology slides were scanned using a Hamamatsu Nanozoomer 2.0-HT slide
scanner (C9600) before scoring, and were viewed using the NDP.view2 software
(Hamamatsu Photonics, Hamamatsu, Japan). Each field was defined to consist of at
least half CTVT parenchyma, avoiding areas of artefactual distortion, ulceration or
haemorrhage. The number of mitotic figures (including bizarre mitotic figures) per
10 high-power fields (40×, a mitotic box of area 0.0325 cm2, perimeter 722 µm on
NDP.view2) was assessed. Statistical significance was tested using an unpaired two-
tailed Student’s t test implemented in R41.
CTVT response to vincristine chemotherapy treatment. A blinded study fol-
lowing response to vincristine chemotherapy in 53 CTVT tumours (4 A1d1a CTVTs
and 49 CTVT_HT1 and CTVT_HT2 CTVTs) was performed in Belize and Colombia
(13 CTVTs in Belize, 40 CTVTs in Colombia). CTVT tumours were treated weekly
with intravenous vincristine sulfate (dose 0.02–0.025mg/kg or 0.5mg/m2), and the
time in days taken for the tumour to reduce to 50% of its original volume was
measured (Supplementary Fig. 8). A single tumour belonging to the CTVT_HT1 and
CTVT_HT2 group that did not reach 50% of its original volume within the study
period was excluded from this analysis. The mitochondrial haplotype of each tumour
was determined retrospectively by genotyping. Statistical significance was tested using
an unpaired two-tailed Student’s t test implemented in R41.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Whole-exome sequence data have been deposited in the European Nucleotide Archive
(ENA) under accession number ERP109580. PacBio long-read sequence data have been
deposited in ENA under accession number ERP120021. Gene expression data have been
deposited in ArrayExpress under accession number E-MTAB-9037. The remaining data
supporting the findings of this study are available within the article and its
supplementary information files.
Code availability
The code used for the A1d1a horizontal transfer frequency modelling analysis is available
at https://github.com/TransmissibleCancerGroup/Mixed.
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